FIELD: medicine.
SUBSTANCE: invention refers to medicine, specifically to endocrinology, radiology, therapy. It involves physical examination of a patient. A percentage of iodine-131 test dose capture in 4 hours, a percent of iodine-131 test dose capture in 24 hours, ultrasound thyroid size, blood free thyroxine (pmol/l), duration of the disease, sex of the patient, duration of thyrostatic withdrawal before a therapeutic dose of radioiodine-131, age of the patient at a first manifestation of said disease, presence of thyroid resection in anamnesis, mercasolyl (thyrozol) dose just before drug withdrawal. Further, upper and lower limits of recommended individual radioiodine (I) dosage range for the certain patient. The lower dosage limit is derived from solving a problem of predicting a dose for negative therapeutic effect events, and the upper limit - for positive effect events. The reliability of positive or negative therapeutic effect is estimated by the prescribed dosage on the basis of solving the classification problem wherein a clinical data base of the prescribed doses supplements input data composition. The therapeutic effect is considered to be an output parametre, while the reliability estimation is represented in the form of a number range 0 to 1; a zero value of the range is interpreted as the negative effect, while the unit value shows the positive effect. The calculated range of the recommended doses is specified by examining the doses in vicinities of the borders with a preset dose look providing therapy confidence as 0.5 for the left border and 0.9 for the right border. The recommended dose is that one that corresponds to the right border of the specified range of the recommended doses.
EFFECT: method provides higher accuracy of individual dosage ensured by considering a great amount of patient's parametres having an action on the therapeutic effect.
3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DETERMINING INDIVIDUAL ACTIVITY OF 131-IODINE FOR RADIOIODINE THERAPY OF THYROTOXICOSIS AND PREDICTION OF TIME FOR ACHIEVING A SAFE LEVEL OF 131-IODINE ACTIVITY IN THE PATIENT'S BODY AFTER ADMINISTERING INDIVIDUAL 131-IODINE ACTIVITY | 2019 |
|
RU2722568C1 |
METHOD FOR PREDICTING RADIOIODINE THERAPY FOR GRAVES' DISEASE | 2022 |
|
RU2791390C1 |
METHOD FOR DIFFERENTIAL DIAGNOSIS OF IODINE-DEFICIENCY AND IODINE-INDUCED THYROID DYSFUNCTION IN INDIVIDUALS LIVING IN REGIONS WITH IODINE DEFICIENCY | 2019 |
|
RU2728261C2 |
METHOD FOR PERSONALIZED APPROACH TO CHOOSING METHOD FOR TREATMENT OF GRAVES DISEASE | 2022 |
|
RU2794815C1 |
METHOD FOR CONTROLLING RADIO IODINE THYROID GLAND CARCINOMA METASTASES THERAPY DISEASES IN MAXILLOFACIAL AREA | 2006 |
|
RU2317115C1 |
METHOD OF ESTIMATING EFFICIENCY OF DIFFUSE TOXIC GOITER THERAPY WITH RADIOACTIVE IODINE | 2008 |
|
RU2373848C1 |
METHOD FOR DIFFUSE TOXIC GOITER COMPLEX TREATMENT | 2016 |
|
RU2614850C1 |
METHOD FOR PREDICTION OF CLINICAL COURSE OF ENDOCRINE OPHTHALMOPATHY IN PATIENTS WITH GRAVES DISEASE BY DETECTING ANTI-THYROID PEROXIDASE ANTIBODIES | 2011 |
|
RU2460072C1 |
METHOD FOR DIAGNOSING THYROID GLAND HYPERFUNCTION | 1994 |
|
RU2106109C1 |
METHOD OF DETERMINING VOLUME OF FUNCTIONAL TISSUE OF THYROID GLAND | 2009 |
|
RU2408269C2 |
Authors
Dates
2011-05-10—Published
2009-10-16—Filed